GLP-1 agonists: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
Neil.m.young (talk | contribs) (Text replacement - "* " to "*") |
||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
* Synthetic glucagon-like peptide-1 (GLP-1) receptor agonists | *Synthetic glucagon-like peptide-1 (GLP-1) receptor agonists | ||
* Released by L-cells of the small intestinge in response to the presence of nutrients | *Released by L-cells of the small intestinge in response to the presence of nutrients | ||
* Stimulate insulin release from pancreatic islet cells. It does this by stimulating glucose-dependent insulin release in the islet cells of the pancreas | *Stimulate insulin release from pancreatic islet cells. It does this by stimulating glucose-dependent insulin release in the islet cells of the pancreas | ||
* Slows gastric emptying times | *Slows gastric emptying times | ||
* Increases satiety, which decreases drive for food intake | *Increases satiety, which decreases drive for food intake | ||
==Types== | ==Types== | ||
| Line 25: | Line 25: | ||
==Indication== | ==Indication== | ||
* Diabetes Mellitus, Type 2 | *Diabetes Mellitus, Type 2 | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
* Nausea, vomiting, diarrhea | *Nausea, vomiting, diarrhea | ||
* Acute pancreatitis | *Acute pancreatitis | ||
* Exenatide should not be used in patients with creatinine clearance below 30mL/min | *Exenatide should not be used in patients with creatinine clearance below 30mL/min | ||
* Should not be used if personal of family history of medullary thyroid cancer or MEN 2A/2B | *Should not be used if personal of family history of medullary thyroid cancer or MEN 2A/2B | ||
==See Also== | ==See Also== | ||
Revision as of 15:49, 27 October 2016
Background
- Synthetic glucagon-like peptide-1 (GLP-1) receptor agonists
- Released by L-cells of the small intestinge in response to the presence of nutrients
- Stimulate insulin release from pancreatic islet cells. It does this by stimulating glucose-dependent insulin release in the islet cells of the pancreas
- Slows gastric emptying times
- Increases satiety, which decreases drive for food intake
Types
| Short Acting | Dose |
|---|---|
| Exenatide(Byetta) | 5-10 mcg SC bid |
| Liraglutide(Victoza) | 0.6-1.8 mg SC daily |
| Long Acting | |
| Exenatide(Bydureon) | 2 mg SC qwk |
| Albiglutide(Tanzeum) | 30-50 mg SC qwk |
| Dulaglutide(Trulicity) | 0.75-1.5 mg qwk |
Indication
- Diabetes Mellitus, Type 2
Adverse Reactions
- Nausea, vomiting, diarrhea
- Acute pancreatitis
- Exenatide should not be used in patients with creatinine clearance below 30mL/min
- Should not be used if personal of family history of medullary thyroid cancer or MEN 2A/2B
See Also
References
1.Epocrates